Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
Launched by THOMAS BENFIELD · May 5, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called MENPI, is studying how safe and effective two different vaccination regimens are for adults living with HIV. Specifically, it looks at vaccines for meningococcal and pneumococcal infections in people who are receiving treatment for HIV. Participants will be randomly assigned to receive either a series of two specific meningococcal vaccines or a different combination of pneumococcal vaccines. After the initial doses, participants will switch to the other vaccine regimen after 90 days. The goal is to see how well these vaccines work and if there are any side effects over time.
To join the trial, participants must be at least 18 years old, have a confirmed HIV infection, and be on antiretroviral treatment with controlled virus levels. They should not have had recent vaccinations for these infections or certain health conditions that could complicate the study. During the trial, participants will have regular check-ups, including blood tests and monitoring for any health issues. This study is important because it aims to improve vaccination strategies for people living with HIV, ensuring they are protected against serious infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Seropositive for HIV-1
- • Recipient of ART
- • Plasma HIV-RNA \< 500 copies/ml
- • Patients written consent obtained
- Exclusion Criteria:
- • Pregnancy or breastfeeding
- • History of meningococcal or pneumococcal vaccination
- • Allergies towards any of the vaccine components
- • Temperature \> 38 ᵒC
- • Sign of bacterial infection
- • Previous known or suspected disease caused by N. meningitidis
- • Active AIDS associated illness
- • Active malignancy
- • End-stage renal or liver disease
- • Bleeding disorder
- • Recipient of any blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within the last month
- • Use of immunosuppressive agents (corticosteroids, cancer chemotherapeutic agents etc.)
About Thomas Benfield
Thomas Benfield is a distinguished clinical trial sponsor known for its commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, the organization emphasizes rigorous study design and ethical conduct in clinical trials. Leveraging a team of experienced professionals and strategic partnerships, Thomas Benfield aims to facilitate the development of safe and effective treatments across various medical disciplines. Their dedication to excellence and patient-centered research positions them as a leader in the clinical trial landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hvidovre, , Denmark
Patients applied
Trial Officials
Michaela Tinggaard, M.D.
Principal Investigator
Department of Infectious Diseases, Hvidovre Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials